Beyond scFvs, nanobody-based CARs offer improved receptor stability, lower immunogenicity, and strong antigen recognition: Cheng et al. developed CD70-specific nanobody-based CAR-T cells for AML that showed potent anti-leukemic activity and suggested combinatorial epigenetic upregulation of CD70 to enhance efficacy [62]. Here, CD70 is linked to acute myeloid leukemia.